Literature DB >> 12522143

Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.

Niels Bovenschen1, Ria C Boertjes, Gunny van Stempvoort, Jan Voorberg, Peter J Lenting, Alexander B Meijer, Koen Mertens.   

Abstract

Low-density lipoprotein receptor-related protein (LRP) is an endocytic receptor that binds multiple distinct ligands, including blood coagulation factor VIII (FVIII). FVIII is a heterodimeric multidomain protein that consists of a heavy chain (domains A1, a1, A2, a2, and B) and a light chain (domains a3, A3, C1, and C2). Both chains contribute to high-affinity interaction with LRP. One LRP-interactive region has previously been located in the C2 domain, but its affinity is low in comparison with that of the entire FVIII light chain. We now have compared a variety of FVIII light chain derivatives with the light chain of its homolog FVa for LRP binding. In surface plasmon resonance studies employing LRP cluster II, the FVa and FVIII light chains proved different in that only FVIII displayed high-affinity binding. Because the FVIII a3-A3-C1 fragment was effective in associating with LRP, this region was explored for structural elements that are exposed but not conserved in FV. Competition studies using synthetic peptides suggested that LRP binding involves the FVIII-specific region Lys(1804)-Ala(1834) in the A3 domain. In line with this observation, LRP binding was inhibited by a recombinant antibody fragment that specifically binds to the FVIII sequence Glu(1811)-Lys(1818). The role of this sequence in LRP binding was further tested using a FVIII/FV chimera in which sequence Glu(1811)-Lys(1818) was replaced with the corresponding sequence of FV. Although this chimera still displayed residual binding to LRP cluster II, its affinity was reduced. This suggests that multiple sites in FVIII contribute to high-affinity LRP binding, one of which is the FVIII A3 domain region Glu(1811)-Lys(1818). This suggests that LRP binding to the FVIII A3 domain involves the same structural elements that also contribute to the assembly of FVIII with FIXa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522143     DOI: 10.1074/jbc.M212053200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

2.  Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.

Authors:  James H Kurasawa; Svetlana A Shestopal; Elena Karnaukhova; Evi B Struble; Timothy K Lee; Andrey G Sarafanov
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

3.  Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Authors:  Maartje van den Biggelaar; Jesper J Madsen; Johan H Faber; Marleen G Zuurveld; Carmen van der Zwaan; Ole H Olsen; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2015-04-21       Impact factor: 5.157

4.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.

Authors:  Patricia A Young; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-10-29       Impact factor: 5.157

5.  Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure.

Authors:  Gilbert C White
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

6.  PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.

Authors:  Aaron Peng; Matthew P Kosloski; Genki Nakamura; Hong Ding; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2011-12-16       Impact factor: 4.009

7.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

8.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

9.  Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36.

Authors:  Keiji Nogami; Katsumi Nishiya; Evgueni L Saenko; Masahiro Takeyama; Kenichi Ogiwara; Akira Yoshioka; Midori Shima
Journal:  J Biol Chem       Date:  2009-01-06       Impact factor: 5.157

10.  Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

Authors:  James R Fuller; Kevin E Knockenhauer; Nina C Leksa; Robert T Peters; Joseph D Batchelor
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.